JP2025501372A - 多重特異性構築物及びその方法 - Google Patents

多重特異性構築物及びその方法 Download PDF

Info

Publication number
JP2025501372A
JP2025501372A JP2024541042A JP2024541042A JP2025501372A JP 2025501372 A JP2025501372 A JP 2025501372A JP 2024541042 A JP2024541042 A JP 2024541042A JP 2024541042 A JP2024541042 A JP 2024541042A JP 2025501372 A JP2025501372 A JP 2025501372A
Authority
JP
Japan
Prior art keywords
seq
amino acid
antibody
sdab
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024541042A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025501372A5 (cg-RX-API-DMAC10.html
Inventor
ウェンチン ジアン，
ジアン リー，
シー チェン，
ヤン リウ，
ビンシー グオ，
Original Assignee
アイ－エムエービー バイオファーマ カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイ－エムエービー バイオファーマ カンパニー リミテッド filed Critical アイ－エムエービー バイオファーマ カンパニー リミテッド
Publication of JP2025501372A publication Critical patent/JP2025501372A/ja
Publication of JP2025501372A5 publication Critical patent/JP2025501372A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024541042A 2022-01-09 2023-01-09 多重特異性構築物及びその方法 Pending JP2025501372A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/070870 2022-01-09
CN2022070870 2022-01-09
CN2022117334 2022-09-06
CNPCT/CN2022/117334 2022-09-06
PCT/CN2023/071334 WO2023131329A1 (en) 2022-01-09 2023-01-09 Multispecific constructs and uses thereof

Publications (2)

Publication Number Publication Date
JP2025501372A true JP2025501372A (ja) 2025-01-17
JP2025501372A5 JP2025501372A5 (cg-RX-API-DMAC10.html) 2025-11-27

Family

ID=87073282

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024541042A Pending JP2025501372A (ja) 2022-01-09 2023-01-09 多重特異性構築物及びその方法

Country Status (9)

Country Link
US (1) US20250074995A1 (cg-RX-API-DMAC10.html)
EP (1) EP4460527A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025501372A (cg-RX-API-DMAC10.html)
KR (1) KR20240133746A (cg-RX-API-DMAC10.html)
CN (1) CN119173539A (cg-RX-API-DMAC10.html)
AU (1) AU2023205989A1 (cg-RX-API-DMAC10.html)
CA (1) CA3248088A1 (cg-RX-API-DMAC10.html)
MX (1) MX2024008500A (cg-RX-API-DMAC10.html)
WO (1) WO2023131329A1 (cg-RX-API-DMAC10.html)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
US11739136B2 (en) * 2019-03-18 2023-08-29 Innovative Cellular Therapeutics Holdings, Ltd. Inducible dominant negative PD-1 and uses in adoptive cell therapy
EP3816185A1 (en) * 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
PH12022552323A1 (en) * 2020-03-31 2023-12-04 Chugai Pharmaceutical Co Ltd Claudin-6 targeting multispecific antigen-binding molecules and uses thereof
EP4138864A4 (en) * 2020-04-23 2024-07-10 Innovative Cellular Therapeutics Holdings, Ltd. Polyspecific binding molecules and their use in cell therapy
WO2021247474A1 (en) * 2020-06-02 2021-12-09 H. Lee Moffitt Cancer Center And Research Institute Inc. Sstr-binding chimeric antigen receptors
CN117355540A (zh) * 2021-05-21 2024-01-05 百济神州有限公司 抗cd137抗体和使用方法
CA3230426A1 (en) * 2021-09-03 2023-03-09 Novarock Biotherapeutics, Ltd. Bispecific binding proteins that bind cd137 and a tumor associated antigen

Also Published As

Publication number Publication date
WO2023131329A1 (en) 2023-07-13
CN119173539A (zh) 2024-12-20
EP4460527A4 (en) 2026-03-11
CA3248088A1 (en) 2023-07-13
EP4460527A1 (en) 2024-11-13
MX2024008500A (es) 2024-08-26
KR20240133746A (ko) 2024-09-04
US20250074995A1 (en) 2025-03-06
AU2023205989A1 (en) 2024-08-01

Similar Documents

Publication Publication Date Title
CN111699200B (zh) 针对pd-1的单域抗体和其变体
WO2019096121A1 (en) Single-domain antibodies and variants thereof against pd-l1
AU2018396964B2 (en) Antibodies and variants thereof against PD-L1
JP7702961B6 (ja) 抗ｃｄ１３７コンストラクト、多重特異性抗体及びその使用
US12247060B2 (en) Calreticulin binding constructs and engineered T cells for the treatment of diseases
CN113825774A (zh) 抗cd47/抗pd-l1多抗原结合蛋白及其使用方法
KR20240163119A (ko) 항-msln 항체 및 사용 방법
CN114008080B (zh) 抗pd-l1/抗lag-3多抗原结合蛋白及其使用方法
EP3178848A1 (en) Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
WO2024061297A1 (en) Anti-b7h3 antibodies, multispecific antibodies and methods of use
WO2023109901A1 (en) Anti-ox40 antibodies and methods of use
US20250074995A1 (en) Multispecific constructs and uses thereof
JP2024509191A (ja) 抗ｖｉｓｔａ構築物およびその使用
WO2026092728A1 (en) Anti-igf-1r antibody constructs and uses thereof
WO2024051752A1 (en) Multispecific constructs and uses thereof
JP2025531788A (ja) 抗ｖｉｓｔａコンストラクト及びその使用
HK40108627A (zh) 抗vista的构建体及其用途
CN118488965A (zh) 抗ox40抗体、多特异性抗体及其使用方法
HK40069847A (en) Anti-ly6g6d antibodies and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251118